Duodenal Jejunal Bypass for Type 2 Diabetes (DJBD)

Ferzli, George S., M.D. F.A.C.S.50 enrolled

Overview

Study the effect of Duodenal jejunal bypass on human adults with type 2 diabetes.

Adults non obese ( BMI less than 34 ) will undergo duodenal jejunal bypass. The Outcome measures: Blood Sugar, Insulin,HbA1c, CCK,Gastrin, GIP1and 2, Ghrelin, Cholesterol, Triglycerides,FFA, C-Peptide.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Diabetes Mellitus

Interventions

duodenal jejunal bypassPROCEDURE

Eligibility

Sex: ALLMin age: 20 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults age 20-65 * Clinical diagnosis of type 2 diabetes * Non obese with BMI less than 34. * Oral agents or insulin to control T2DM. * Inadequate control of diabetes as defined as HbA1c\>/7.5 * Understanding of the mechanisms of action of the treatment Exclusion Criteria: * Children with type 1 diabetes * Obese with BMI over 34 * Coagulopathy * Liver cirrhosis * Unable to comply with study requirements, follow-up or give valid consent * Currently pregnant * Previous upper abdominal surgery * Inabilty to tolerate general anesthesia

Locations (1)

Center for Advance Medicine Abel Gonzalez

Santo Domingo, Dominican Republic

RECRUITING

Outcomes

Primary Outcomes

control of type 2 diabetes in non obese adults

Time frame: two years

Secondary Outcomes

CCK FFA,Cholesterol,Ghrelin,C-peptide,HbA1c,Gastrin,GIP,Triglycerides,Insulin

Time frame: 2 years

Central Contacts

George S Ferzli, MD, F.A.C.S

CONTACT

718-667-8100 GFerzli@aol.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.